Noxxon Pharma Ag

3b Pharmaceuticals Gmbh

Aptarion Biotech Ag

Dirk Zboralski

Christian Maasch

Werner Purschke

Sven Klussmann

Florian Jarosch

Klaus Buchner

Dirk Eulberg

Axel Vater

Nicole Dinse

Ulrich Reineke

Frank Osterkamp

Kai Hohlig

Matthias Paschke

Christiane Smerling

Christian Haase

Aileen Höhne

Anne Bredenbeck

Jan Ungewiss

Eberhard Schneider

The present invention is related to a compound comprising a cyclic peptide and a chelator, and its use.

Compounds comprising a fibroblast activation protein ligand and use thereof

The present invention is related to an L-nucleic acid molecule capable of binding to human CXCL8, wherein the L-nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5'-GG A AGU ACGUGGA AAGCCRA(Xu)RAGUGUGUCCCG-3′[SEQ. ID. NO: 27], wherein Xu is U or absent.

CXCL8 binding nucleic acids

The present invention is related to a molecule capable of inhibiting signaling between SDF-1 and CXCR4 and/or CXCR7, wherein the molecule is for use in a method of modulating the number and/or the spatial distribution of tumor-infiltrating leukocytes in a tumor and/or metastases.

Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors

The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.

SDF-1 binding nucleic acids and the use thereof in cancer treatment

Growing community of inventors

Berlin, Germany

Dirk Zboralski